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Introduction
Lymphomas are elegant models to develop and test
new diagnostic approaches in oncology. We here dis-
cuss a patient with a lymphoproliferative syndrome
with an unusually long clinical evolution marked by
repetitive periods of spontaneous remissions over
many years before finally turning into chronic B-cell
lymphocytic leukaemia. We believe that this case pro-
vides an interesting basis to review several distinct and
yet related clinical and biological problems in lym-
phoma.
Case report
In 1984, a 49-year-old previously healthy woman suf-
fered from abdominal pain, fever, general weakness,
splenomegaly and enlarged lymph nodes. A viral infec-
tion was suspected. The abnormalities subsided rapidly
and fully without any treatment, and the patient de-
clined any further investigations at that stage. In 1988,
generalized lymphadenopathy and splenic enlargement
accompanied by fever recurred, and the patient agreed
to have a first lymph node biopsy taken which was
thought to be inconclusive at that time. In subsequent
years her clinical course was characterized by repetitive
bouts of 2-3 weeks duration with fever, night sweats,
generalized lymphomas measuring up to several cm,
and marked splenomegaly. Subsequent lymph node
biopsies yielded the diagnosis of a low grade B-cell
lymphoma. In between these episodes all symptoms
regularly subsided without any treatment, and lympho-
mas as well as the spleen completely regressed to their
normal size. Typically, the patient did well for periods
of up to 2-3 months until the full clinical picture re-
turned. She received no therapy for several years, but
later a few of these many episodes were treated with
short pulses of low dose prednisone to shorten the
periods of discomfort due to fever and night sweats.
She usually responded with clinical remission of both
symptoms and physical signs of disease, but her physi-
cians felt it was difficult to decide whether such im-
provement was due to treatment or not. In 1994, 10
years after her first symptoms and clinical signs due to
lymphoma had appeared, she developed chronic B-cell
lymphocytic leukaemia with peripheral blood lympho-
cytosis, bone marrow infiltration, multiple lymphomas,
splenomegaly, and a typical immunophenotype (stage
Rai H/Binet B). She was treated with chlorambucil and
prednisone because of her B-type symptoms and large
lymphoma masses. She responded with a partial remis-
sion. Treatment results were assessed both clinically
and radiologically documenting a significant regression
of lymphomas and splenic size as well as a reduction
(but no eradication) of lymphoid cellular infiltrates in
the marrow. Treatment was stopped after 8 chemother-
apy cycles because of progressive disease. At that stage
she developed acute pancreatitis of unknown cause and
septicaemia, and she died in March 1995. An autopsy
was not permitted by her family.
Lymph node biopsies were taken in 1988, 1989,
1991 and in 1993 with bone marrow biopsies. In 1988,
no conclusive morphological diagnosis was made. The
pathologist described reactive alterations compatible
with a viral infection characterized with lymphoid
hyperplasia, but also effacement of normal lymph node
structure suspicious of lymphoma. However, in an en-
larged lymph node excised in 1989 and in later biop-
sies a low grade stage IVB non-Hodgkin's lymphoma
was diagnosed with diffuse infiltration of the bone mar-
row. Serological searches for HTV, cytomegalovirus,
and toxoplasmosis were always negative. Interestingly,
in 1988 there was serological evidence of acute infec-
tious mononucleosis, and both the clinical picture as
well as the lymph node morphology were thought to be
compatible with acute EBV-infection at that stage.
During later years serological follow-up tests showed
an IgG pattern typical for a previous EBV-infection
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without any signs of re-activation. Serum protein elec-
trophoresis showed polyclonal elevation of IgG for
many years, but as of 1994 small additional peaks of
monoclonal paraproteins (IgM K and IgG X) appeared.
Diagnostic work-up
Serial lymph node biopsies and blood leukocyte sam-
ples taken over several years gave us the opportunity to
employ various standard and novel diagnostic tech-
niques to study this lymphoma and its evolution over
time.
Morphology and immunological analysis
Upon morphological review (performed by B.B.) all
lymph node biopsies (1988, 1989, 1991, and 1993)
showed effacement of lymph node structure by small
lymphoid cells homogeneously distributed all over
the nodes (Figure 1). Paraffin and cryostat sections
were immunophenotyped with anti-B-cell antibodies
(CD10, CD19, CD20, CD22, CD23, CD45R, KiB3,
IgG, IgM, IgD, IgA, and anti-K as well anti-X) and anti-
T-ceil antibodies (UCHL, CD2, CD3, CD4, CD5,
CD8, MT1 and CD45RO). Other markers employed
were EBV-LMP (Epstein Barr Virus latent membrane
protein), IL2-R (activation marker), Ki67 and MIBl
(proliferation markers), and CD21 (follicular dendritic
cell marker). On immunohistochemistry the cells were
of B-phenotype and admixed with reactive T-cells in all
the biopsies. Hardly any remnants of networks of fol-
licular dendritic cells were found. The tumour cells
exclusively expressed surface Ig K light chains but vir-
tually no X chains (Figure 2). The proportion of prolif-
erative cells (Ki67, MIBl) was low. Thus, the diagnosis
Figure 1. Giemsa stain of a lymph node section. There is total
effacement of the normal lymph node structure and a dense infiltra-
tion by small lymphoid cells homogeneously distributed all over the
node. The histological appearance corresponds to a low grade non-
Hodgkin's lymphoma (International Working Formulation: Type A,
small lymphocytic; R.E.A.L. classification: peripheral B-cell neo-
plasm, small lymphocytic lymphoma/B-cell chronic lymphocytic
leukaemia) [1,2].
Figure 2. Immunohistochemical staining of a lymph node section
with an anti-Ig K light chain antibody (avidin-biotin method with
diaminobenzidine as a chromogenic substance). Virtually all small
lymphoid cells show light brown staining on the cell curface with the
antibody, indicating exclusive monoclonal expression of K light
chains (no X light chain positivity. X light chain stain not shown) [13-
15].
of a low grade B-cell non-Hodgkin's lymphoma was
confirmed (International Working Formulation: type
A, small lymphocytic; R.EA.L. classification: periph-
eral B-cell neoplasm, small lymphocytic lymphoma/B-
cell chronic lymphocytic leukaemia [1, 2]). The contro-
versial biopsy taken in 1988 was carefully reviewed and
the material typed with additional markers. Although it
had initially been reported as representing a possibly
polyclonal lymphoproliferation of perhaps viral aetiol-
ogy, this view was revised and the histology found to be
fully compatible with the diagnosis of the same malig-
nant lymphoma established in later biopsies. The find-
ing of monoclonal immunoglobulin (Ig) gene rear-
rangements in this material further strengthens this
view (see Discussion). In the final phase of the illness,
marked lymphocytosis was present in the peripheral
blood. Immunophenotyping of peripheral blood lym-
phocytes by flow cytometry revealed predominant
B-cells with co-expression of CD5 (Table 1 and Figure
3). In addition, a minority of B-cells weakly expressed
cytoplasmic X chains but no K chains (X/K ratio >6:1).
Based on the finding of a B-cell expansion with partial
loss of CD20, co-expression of CD5, and predomi-
nance of Ig X light chain expression typical B-cell chro-
nic lymphocytic leukaemia was diagnosed (Table 2).
Molecular analyses
DNA of all lymph node biopsies and of peripheral
blood leukocytes (before and after CLL was diag-
nosed) was examined by Southern blotting and the
polymerase chain reaction (PCR) to detect Ig heavy
chain and T-cell receptor (TCR) gene rearrangements
(Figure 4) [3-6]. All DNA samples taken between
1988 and 1995 showed identical Ig heavy chain gene
rearrangements by Southern blotting indicating the
presence of a clonal population of lymphoid cells
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Table 1. Immunophenotype results by flow cytometry of the pa- Discussion
dent's peripheral blood lymphoid cells at a late stage when morpho-
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Figure 3. Immunophenotype analysis by flow cytometry of periph-
eral blood lymphoid cells. The cells were labelled with monoclonal
anti-CD5 and anti-CD19 antibodies. Lymphoid cells were selected
for analysis by electronic gating based on cell size and granularity.
The two antibodies were coupled with different dyes permitting
separate analysis in the flow cytometer (CD 19: green fluorescence;
CD5: orange fluorescence). Left panel: peripheral blood lymphoid
cells from a normal person. Note that a population of B-cells (posi-
tive for CD 19; quadrant B4) and a separate population of T-cells
(positive for CD5; quadrant Bl) are present. Less than 1% of lym-
phoid cells are double positive for CD19 and CDS (quadrant B2). A
minority of lymphoid cells (corresponding largely to natural killer
cells) express neither CD19 nor CD5 (quadrant B3). Right panel:
peripheral blood lymphoid cells from the patient in a sample where
CLL was suspected based on morphology. The vast majority of lym-
phoid cells co-express CD19 and CD5 (quadrant B2) typical of
B-cell CLL. Note that a small population of normal T-cells positive
for CD5 only is also present (quadrant Bl).
(Figure 5). This result was confirmed by amplification
of rearranged Ig heavy-chain gene fragments by immu-
nogenotype PCR (Figure 6). No TCR gene rearrange-
ments or deletions were detected. Analyses (Southern
blot and PCR) for the presence of EBV genome in the
neoplastic celJs were negative.
The clinical course of our patient was noteworthy for
its relatively favourable evolution over many years
characterised by spontaneously waxing and waning
lymphomas and splenomegaly. Cases of clonal low
grade malignant non-Hodgkin's lymphoma with a clini-
cally benign course and spontaneous regressions have
been repeatedly described [7, 8]. Clonal lymphoprolif-
erations need not necessarily show malignant behavi-
our clinically as illustrated by several distinct clonal yet
benign lymphoproliferative syndromes well known to
dermatologists [9-12]. In our patient, a favourable
long-term evolution and the pathologist's morpho-
logical diagnosis of a cancer at times seemed a bit diffi-
cult to be reconciled, but the review of the morphologi-
cal findings in the successive lymph node biopsies in
conjunction with immunogenotype findings, and the
clinical evolution into B-CLL clearly argue in favour of
a malignant lymphoma.
Recently, a very interesting case of mantle zone lym-
phoma reminiscent of our patient's story and similarly
characterized by recurrent cycles of acute illness alter-
nating with spontaneous remissions was reported [8].
Two B-cell (sub-)clones were identified that had origi-
nated from a single malignant clone. One of them was
stably present whereas the other one (marked by an
individual-specific Ig gene rearrangement) appeared
during acute phases only. Presumably these neoplastic
cells were eliminated through programmed cell death
activated in vivo at the peaks of the acute phases. The
generation of autoantibodies with anti-idiotypic activ-
ity may perhaps play a role in such cases. Chronic viral
infections might provide signals to induce initiation of
lymphoma growth, followed by apoptosis and clinical
remission. EBV infection was documented in our pa-
tient by typical antibody patterns in her serum, and
might perhaps have provided such signals to her clonal
B-cells. However, this lymphoma was not an EBV-as-
sociated B-cell lymphoma since no EBV genomic
material was found in her tumour cells.
A few comments on the immunophenotype analysis of
chronic B-cell lymphoproliferative disorders
The demonstration of Ig light chain restriction indi-
cates a monoclonal lymphoid population, i.e., originat-
ing from a single B-cell either expressing K or X chains
but not both [13-17]. Reactive polyclonal accumula-
tions of B-cells in an inflammatory infiltrate would ex-
press K and X Ig light chains at roughly a 2:1 to 1:1 ratio
[13, 17]. Ig light chain restriction is considered the
single most useful criterion for the immunophenotypic
diagnosis of B-cell malignancies [3, 17, 18] although
monoclonal Ig light chain expression has also been
reported in rare cases of reactive lymphoid hyperplasia
[19, 20]. It can easily be investigated by flow cytometry
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Table 2. Low-grade B-cell lymphomas: immunohistological and genetic features in differential diagnosis [1,16,22].
Lymphoma Ig Igcyto- CD5 CD10 CD19 CD23 Typical chromosomal
surface plasmic (CALLA) aberration
B-CLL or small lymphocytic lymphoma +
Lymphoplasmacytoid lymphoma or immunocytoma +
Mantle cell lymphoma or centrocytic lymphoma +
Follicle center lymphoma or follicular lymphoma +



















Figure 4. Schematic representation of the detection of Ig gene rearrangements by Southern blot and PCR [3-6, 11, 32, 33]. A) Ig heavy
chain gene on chromosome 14 in the germline configuration. V - variable regions; D - diversity regions; J - joining regions; C(i - constant
region. The restriction enzyme EcoRI cuts a 16 kb germline DNA fragment recognized by an Ig heavy-chain joining region probe (JH-
probe). B) Hypothetical Ig heavy-chain gene rearrangement resulting in specific V-D-J joining. Note that the size of the EcoRI fragment
described in A is altered to a smaller fragment also recognized by the JH-probe. C) JH-probe commonly used to detect the germline Ig
heavy-chain joining region and its rearrangements with the Southern blot technique. D) Primers used for immunogenotype PCR. The primer
pair can be used to amplify most rearrangements at this locus. Note that an Ig heavy-chain gene rearrangement results in a much smaller dis-
tance between the FR3A (framework 3A) consensus primer and the LJH primer which is amenable to copying by the polymerase.
and immunohistochemistry both on the surface and in
the cytoplasm of cells [21-24]. However, light chain
expression may be very weak (as in our patient) or even
absent in neoplastic cells, rendering analysis of mono-
clonality by flow cytometry difficult or impossible. The
interpretation of the results in our patient seems diffi-
cult at first sight. The lymphoma cells showed exclusive
expression of Ig K light chains whereas the B-CLL cells
predominantly expressed Ig X light chains. A glance at
the 1994 serum electrophoreses provides a possible
clue: in addition to the former single monoclonal Ig K
light chain peak an additional separate clonal X peak
was now present, indicating two B-cell subclones. Such
clonal evolution of lymphomas over time implies that
patterns of clonal markers, for example monoclonal
paraprotein peaks identified in a serum protein electro-
phoresis may change over time.
In order to differentiate between B-CLL and other
B-cell neoplasms particular patterns of immunological
markers may be helpful (Table 2) [1, 14, 17]. A scoring
system considers three immunological markers (CD5,
CD23, and FMC7) and the intensity of surface Ig and
surface CD22 expression. The sum of the scoring
points correlates with the likelihood that a diagnosis of
CLL is correct [25] (Table 3). Our patient had a score
of 5 in the leukaemic phase which is virtually diagnostic
of B-CLL. Double-labelling with monoclonal anti-
bodies revealed co-expression of the T-cell associated
marker CD5 by the clonal B-cell population alongside
with typical B-cell markers, for example CD19 (Table 1
and Figure 3). CD5 is also expressed by B-cell sub-
populations in an age-dependent manner, particularly
in cord blood, fetal lymph nodes and liver [26, 27]. In
healthy adults CD5-positive B-lymphocytes constitute
1% to 30% of the total B-cell population in the spleen,
lymph nodes and peripheral blood, but are virtually
absent in bone marrow. A monoclonal expansion of
CD5-positive B-cells is typical for either B-CLL or
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Figure 5. Southern blot detection of clonal Ig gene rearrangements.
P - patient's DNA from B-CLL cells; C - normal control DNA.
Single arrows indicate germline restriction fragments, double arrows
indicate clonally rearranged fragments. Blot hybridized with a DNA
probe (JH) recognizing a fragment from the joining region of the Ig
heavy-chain gene |4-6). The restriction enzyme EcoRI (left side of
the panel) cuts a 16 kb fragment out of the gene (see also map in
Figure 4A). The rearrangement process produces a smaller frag-
ment in the CLL cells. This finding is confirmed using another
enzyme Hindm (right side of panel) which normally yields a 10.5 kb
germline fragment, but in B-CLL DNA shows two rearranged bands
derived from a clonally rearranged Ig gene. The germline bands are
either derived from contaminating normal cells, or represent a non-
rearranged allele in the neoplastic cells, or both.
mantle cell lymphoma [25]. It is noteworthy in this
respect that infectious mononucleosis was present in
our patient six years before CLL was diagnosed. An in-
creased number of polyclonal (or oligoclonal) CD5-
positive B-cells has been reported in patients with
infectious mononucleosis or previous EBV infection
[28], with the hypothesis that clonal lymphomas might
eventually evolve from these reactive disorders. An in-
creased number of CD5-positive B-cells may also be
present after allogeneic bone marrow transplantation
[29] or in rheumatoid arthritis [30].
Table 3. Scoring system for the differential diagnosis of CLL and
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Figure 6. Amplification by PCR of a clonally rearranged Ig heavy-
chain gene fragment [32, 33]. Samples: 1) DNA from normal poly-
clonal lymphocytes; 2) patient's lymphoma DNA from 1993; 3)
lymphoma DNA from 1991; 4) lymphoma DNA from 1989; 5)
molecular fragment size marker. All patient samples reveal the same
190 bp PCR fragment representing a clonal Ig heavy-chain gene
rearrangement that remains constant over time. Note that DNA
from polyclonal lymphocytes does not produce distinct PCR ampli-
fication products but a smear (lane 1). In the germline gene the two
primer annealing sites are too far apart, and therefore the polymer-
ase fails to copy the DNA stretch between them (see Figure 4 for
map).
Assessment of lymphoma clonality with the help of
molecular biology
The detection of antigen receptor gene rearrangements
with molecular probes for Ig and TCR genes has pro-
vided a new powerful tool to assess the clonality of
lymphoproliferative disorders [3-6, 31]. In their germ-
line configuration Ig and TCR genes are composed of
distinct DNA subsegments or regions (constant, diver-
sity, joining and variable regions). Germline genes are
non-functional. In order to produce a functional gene
for the production of a specific antibody or T-cell
receptor protein a lymphoid cell must reassemble the
molecular units of its Ig or TCR genes during matura-
tion (Figure 4). This mechanism is the molecular basis
for the immense diversity of antibodies and TCR pro-
teins which the immune system requires to do its job. Ig
and TCR gene rearrangements are highly specific
markers for a given B- or T-cell passed on to its pro-
geny. A polyclonal lymphoid cell population is com-
posed of myriads of different cells with individually
sized gene rearrangements. On a Southern blot these
various fragments are not detected because each single
rearrangement is far below the sensitivity threshold of
the method. However, if at least 5%-10% of the cells
contribute the very same DNA rearrangement, a dis-
tinct new non-germline band becomes detectable on
autoradiography (Figure 5). Since the chances that
958
Table 4. Assessment of clonality in lymphoproliferations.
Principle Material Method Comment











Cells or tissue samples
including fired material
Fresh cells, fresh tissue or
air-dried bone marrow
smears [38] as a source of
DNA
DNA from fresh or fixed
cells (including degraded
DNA)
Fresh cells or fresh tissue
as a source of DNA
DNA from fresh or fixed
cells (including degraded
DNA depending on frag-
ment size); normal DNA
from the patient must be
available.
Immunophenotyping by flow anal-
ysis or immunohistochemistry
Restriction enzyme digests. South-
ern gel electrophoresis. Hybridiza-
tion with antigen receptor probes.
Amplification of rearranged Ig or
TCR gene sequences
Southern blotting and hybridisa-
tion with EBV-specific probes.
Southern blotting and hybridiza-
tion with X-chromosomal probes,
or PCR of X-chromosomal se-
quences. Testing of inactivation
patterns by examining allele-spe-
cific methylation.
Applicable only to B-cell neo-
plasms which produce Ig light
chain proteins.
Suitable for virtually all stages of
maturation in lymphoid neoplasms.
Laborious technique.
Easiest for Ig heavy-chain gene
rearrangements. Relatively high
rate of false-negative results. TCR
genes can be problematic.
Suitable only in EBV-associated
lymphomas harbouring EBV-DNA
in the tumour cells.
Suitable only in informative fe-
males constitutionally heterozy-
gous for an X-linked DNA poly-
morphism. Non-random patterns
may be seen in normal leukocytes
- assays thus problematic in
haematology [39].
many unrelated lymphoid cells would independently
produce the very same Ig or TCR gene rearrangement
are exceedingly small, a rearranged band points to a
clonal population of lymphoid cells. This phenomenon
may be likened to an 'in vivo' PCR amplification of a
particular gene fragment through clonal expansion of
neoplastic B-cells! A thought or two should be given to
the possible pitfalls of the method as summarized in
Table 5 [5,6]. For example, partial enzyme digestion or
a DNA polymorphism may cause difficulties in inter-
preting the results. In our patient Southern blot analysis
of DNA from all lymph node biopsies and peripheral
blood revealed two non germ-line rearranged bands
that were constant over time, supporting the view that
over ten years (including the final phase of B-CLL) a
clonal lymphoid disorder was present.
The Southern blot findings in our case were con-
firmed by immunogenotype PCR which detected an Ig
heavy chain gene rearrangement constant throughout
the lymphoma samples tested [32, 33]. However, no
germline Ig gene fragment was seen on PCR analysis
(Figure 6). The reason is that in the germline Ig gene
the annealing sites of the primers encompass a frag-
ment far too long to be amplified (the maximum length
of DNA fragments amenable to PCR is in the range of
several hundred to perhaps 1,000 to 2,000 base pairs)
[32]. A somatic rearrangement, however, creates a new
much smaller Ig gene fragment suitable for PCR ampli-
fication, since many DNA segments located between
the primer annealing sites that are not used to create a
functional gene are deleted. A major limitation of PCR
in detecting B-cell clonality is the high rate of false-
negative results ranging from 10%-40% of these cases.
Appropriate choice of the primers and careful control
of gel electrophoresis conditions to visualise clonal Ig
gene fragments appear to be crucial to detect rear-
ranged Ig gene sequences [33, 34]. Once these prob-
lems are satisfactorily addressed PCR will soon be-
come an essential routine tool to examine the clonality
of lymphoid proliferations whilst the Southern blot
technique is too cumbersome and laborious for every
day practice outside specific research protocols. In
practice morphological examination of good-quality
lymph node biopsies and immunohistochemistry with
an appropriate panel of diagnostic antibodies will pro-
vide an accurate diagnosis of a lymphoid tumour in
almost 95% of cases. Molecular analysis of clonality by
Southern blotting of immunogenotype PCR will only
be required to solve diagnostic problems in a rather
small proportion of cases [23].
Two other approaches to assess clonality were tested
in this case. Since the patient had serological evidence
of EBV-infection, her lymphoma DNA was tested for
the presence of clonal patterns of EBV-genome. EBV-
specific probes can visualize virus-specific polymor-
phic sequences as separate bands on Southern blots
[34-36]. Monoclonal EBV-associated lymphoid tu-
mours harbour one such EBV-terminal-repeat frag-
ment only whereas polyclonal lymphocyte populations
infected by different virions show multiple different
bands. The lymphoma DNA of our patient was nega-
tive for EBV-genomic material. Assessment of clonal-
ity by X-inactivation analysis is based on the fact that in
each somatic female cell only one of the two X-chro-
mosomes is active. In polyclonal cell populations
maternal and paternal X-chromosome copies are in-
activated at a ratio of about 1:1 (random) whereas in
clonal tumours all neoplastic cells keep the same
959
Table 5. Southern blots to detect clonal lymphoid proliferations.
Using any combination of restriction enzymes and antigen receptor
gene probes the following possible patterns may be seen on a South-
ern blot autoradiograph [3-6).
1. Germline bands only — no novel bands
No monoclonal gene rearrangement can be detected. Hence, the
specimen must contain
a) non-lymphoid normal or tumour tissue;
b) polyclonal lymphoid cells, for example in inflammatory
conditions;
c) a monoclonal lymphoid population below the detection lim-
its of the Southern method (in the order of magnitude of a
few % of all nucleated cells);
d) a monoclonal lymphoid population with Ig or TCR gene
rearrangements that may not be apparent because their
fragment size is similar to the size of germline fragments.
This problem occurs mainly with large fragments as these
are less well resolved during electrophoresis than smaller
ones. Use of additional restriction enzymes creating differ-
ent fragments will usually offer a solution to this problem;
e) a monoclonal lymphoid cell population with a rearrange-
ment that leads to biallelic deletion of the gene (this is rare -
an example are TCR 6 gene deletions in acute lymphoblas-
tic leukaemia). Examination of several antigen receptor
genes will usually do the trick;
f) another patient's sample that must have been mixed up in
the mail or in the laboratory due to logistic and technical
errors.
2. Both germline and rearranged non-germline bands
This may be seen when
a) monoclonal lymphoid tissue is admixed with normal or
non-lymphoid tissue contributing the germline band;
b) the rearrangement in the clonal cells affects only one allele
of the Ig or TCR gene retaining the other one in the germ-
line configuration.
c) rearranged bands are faked because the restriction enzyme
digest is incomplete leading to 'novel' fragments. Such
'novel' bands are typically larger than the germline fragment
predicted from the restriction map;
d) novel bands are due to a constitutional DNA polymor-
phism. Use of several restriction enzymes, testing of consti-
tutional DNA from the patient (which should contain the
polymorphic bands but no somatic rearrangements) as well
as family studies (tracing the inheritance of polymorphic
alleles) usually solve this problem.
3. Novel rearranged bands only
This pattern occurs in samples that exclusively contain monoclonal
lymphoid populations with biallelic rearrangements of an Ig or TCR
gene.
parental copy in the active state (non-random use of
one X-chromosome) [18, 38]. X-chromosomal poly-
morphisms (constitutional variations in the DNA
sequence within the X-chromosome) suitable for these
clonality tests have been found in the hypoxanthine
phosphoribosyl transferase gene, the phosphoglycerate
kinase gene, an X-chromosomal locus termed M27|3
and in a polymorphic locus within the human androgen
receptor gene. Unfortunately our patient was not infor-
mative for any of these polymorphisms and thus not
suitable for this approach.
Conclusions
This patient offers the opportunity to comment on sev-
eral interesting features of lymphomas. The clinical
course is unusual with many episodes of lymphoma
regression without any treatment over several years.
Such clinical data should be taken into account when
results of lymphoma treatment are interpreted. Al-
though the causes of this phenomenon in our patient
are unknown, programmed cell death or apoptosis trig-
gered by exogenous factors might have played a role in
these conditions [8]. Molecular techniques detected an
Ig gene rearrangement which served as an individual-
specific tag to show that a constant clonal lymphoid
proliferation was present over many years including the
final phase of B-CLL. This illustrates the point that
molecular diagnostics have expanded our armamen-
tarium for the characterisation of such cases [40], al-
though morphology, immunohistochernistry and immu-
nophenotyping are still the diagnostic cornerstones to
study lymphoma. During our work-up of the case the
clonal marker was also detected in the first biopsy
which initially had created some diagnostic difficulties.
The diagnosis of a monoclonal lymphoproliferation
would have helped to overcome these problems at this
early stage. Finally the question arises of whether ear-
lier treatment with cytostatic drugs could have prevent-
ed or postponed the eventually fatal final leukaemic
phase. This seems unlikely with a standard regime such
as chlorambucil and prednisone, but the impact of
newer treatments including purine analogues in this
respect remains to be established.
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